| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 30 May 2026 | 25 May 2026 |
| Vivo Bio Tech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve 1. To consider and approve the Audited Standalone & Consolidated Financial Results of the Company for the Fourth Quarter and Year ended March 31 2026. 2. To consider and approve the amalgamation of M/s. Shri Shri Resorts Private Limited (Transferor Company) with and into M/s. Vivo Bio Tech Limited (Transferee Company) under Sections 230 to 232 and other relevant provisions of the Companies Act 2013 SEBI Listing Regulations etc. Vivo Bio Tech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve 1. To consider and approve the Audited Standalone & Consolidated Financial Results of the Company for the Fourth Quarter and Year ended March 31, 2026. 2. To consider and approve the amalgamation of M/s. Shri Shri Resorts Private Limited (Transferor Company) with and into M/s. Vivo Bio Tech Limited (Transferee Company) under Sections 230 to 232 and other relevant provisions of the Companies Act, 2013, SEBI Listing Regulations etc. (As Per BSE Announcement dated on:29.05.2026 | ||
| Board Meeting | 13 Feb 2026 | 2 Feb 2026 |
| Vivo Bio Tech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve the Un-Audited Standalone & Consolidated Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2025. Un-Audited Standalone & Consolidated Financial Results Of The Company For The Third Quarter And Nine Months Ended December 31, 2025. (As per BSE announcement dated on : 13.02.2026) | ||
| Board Meeting | 14 Nov 2025 | 4 Nov 2025 |
| Vivo Bio Tech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve the Un-Audited Standalone & Consolidated Financial Results of the Company for the Second Quarter and Half Year ended September 30 2025. please find enclosed (As per BSE Announcement dated on: 14.11.2025) | ||
| Board Meeting | 26 Aug 2025 | 26 Aug 2025 |
| Please find enclosed outcome of the Board Meeting | ||
| Board Meeting | 12 Aug 2025 | 6 Aug 2025 |
| Vivo Bio Tech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 inter alia to consider and approve the Un-Audited Standalone & Consolidated Financial Results of the Company for the First Quarter ended June 30 2025. Please find enclosed outcome of board meeting (As per BSE Announcement Dated on 12/08/2025) | ||
| Board Meeting | 2 Jul 2025 | 2 Jul 2025 |
| Please find enclosed Outcome of Board Meeting | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
